Profile | GDS2987 / GI_4557326-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 9.6 | 33 |
GSM215244 | HMVEC_vehicle_rep2 | 15.4 | 37 |
GSM215253 | HMVEC_vehicle_rep3 | 5 | 17 |
GSM215254 | HMVEC_atorvastatin_rep1 | 8.3 | 22 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 12.9 | 21 |
GSM215294 | HMVEC_SLx2119_rep1 | 2.7 | 10 |
GSM215295 | HMVEC_SLx2119_rep2 | 1.7 | 4 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 20.4 | 31 |
GSM215298 | PASMC_vehicle_rep2 | 13.6 | 21 |
GSM215310 | PASMC_vehicle_rep3 | 40.8 | 54 |
GSM215311 | PASMC_atorvastatin_rep1 | 29.2 | 46 |
GSM215312 | PASMC_atorvastatin_rep2 | 43.8 | 56 |
GSM215313 | PASMC_atorvastatin_rep3 | 24.3 | 35 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 47 | 59 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 23.5 | 42 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 5 | 9 |
GSM215327 | PASMC_SLx2119_rep1 | 43.7 | 59 |
GSM215328 | PASMC_SLx2119_rep2 | 10.2 | 19 |
GSM215329 | PASMC_SLx2119_rep3 | 38.3 | 57 |
GSM215330 | Fibroblasts_vehicle_rep1 | 10 | 24 |
GSM215331 | Fibroblasts_vehicle_rep2 | 16.2 | 42 |
GSM215332 | Fibroblasts_vehicle_rep3 | 5.6 | 19 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 20.6 | 45 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 16.8 | 48 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 4.4 | 15 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | 20.5 | 49 |
GSM215341 | Fibroblasts_SLx2119_rep3 |